Список проголосовавших за комментарий " Gapping up/down: NEPT +14% after earnings, P +8% after guidance and M&A spec, NFLX and FB +1% after upgrades; WFC and BAC -1% after earnings, DG -1% after dg at BofA<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>NEPT</strong> +13.8%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>P</strong> +7.8% (Sirius XM (SIRI) might be interested in acquiring Pandora, according to NY Post, also expects to exceed Q4 guidance)</li><li><strong>SN</strong> +7.8% (Anadarko Petroleum to sell Eagleford Shale assets in South Texas for approx $2.3 bln to Sanchez Energy and Blackstone Group),</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>RXII</strong> +40.4% (OPKO Health (OPK) increases stake to 5.11% (Prior 3.43%), changes shareholding position to passive from active)</li><li><strong>TBIO</strong> +27.7% (continued momentum)</li><li><strong>TTNP</strong> +22% ( CMC has granted a opermanent J-code for Probuphine)</li><li><strong>IOTS</strong> +5.3% (after ~50% move higher on Thursday)</li><li><strong>OPXA</strong> +5.2% (following late move higher into the close)</li><li><strong>OREX</strong> +4.4% (after spiking higher into the close)</li><li><strong>NVLS</strong> +4.1% (approved a restructuring plan as part of the Company's initiative to explore strategic alternatives; cutting 25 of 30 emplyees, including the CEO and CMO)</li><li><strong>IMMU</strong> +3.8% (continued momentum)</li><li><strong>ZIOP</strong> +3.6% ( following Najarian mention on CNBC)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>MBLY</strong> +2.8% (initiated with a Buy at Jefferies)</li><li><strong>GRUB</strong> +2.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley)</li><li><strong>CNHI</strong> +2% (upgraded to Neutral from Underperform at BofA/Merrill )</li><li><strong>NOK</strong> +1.5% (upgraded to Buy from Neutral at Natixis)</li><li><strong>NFLX</strong> +1.2% (upgraded to Hold at Deutsche Bank)</li><li><strong>CIEN</strong> +0.7% (initiated with a Buy at UBS)</li><li><strong>FB</strong> +0.7% (upgraded to Strong Buy from Outperform at Raymond James)</li></ul><p><strong>Gapping down<br/> In reaction to disappointing earnings/guidance</strong>:</p><ul><li><strong>GME</strong> -7%, <strong>HMST</strong> -3.1%, (reports downside Q4 results and announces proposed settlement of SEC investigation)</li><li><strong>FHN</strong> -2.8%, <strong>INFY</strong> -1.6%, <strong>WFC</strong> -1.1%, <strong>BAC</strong> -0.8%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>WPX</strong> -0.9% (will acquire assets that are expected to increase its Permian operations; commences underwritten public offering of 42 mln shares of its common stock),</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>URRE</strong> -24.6% (proposes public offering of common stock; actual size or terms of the offering not yet determined)</li><li><strong>SKLN</strong> -15.6% (Skyline Medical will hold a conference call on January 19 at 4:30pm ET to provide a business update and a discussion on recent and upcoming milestones; prices public offering of 1,750,000 units at an offering price of $2.25/unit)</li><li><strong>MRNS</strong> -11.4% (following late move higher into the close)</li><li><strong>FCEL</strong> -2.6% (files for $150 mln mixed securities shelf offering)</li><li><strong>OOMA</strong> -2.2% (announces that certain of its stockholders, consisting of entities affiliated with Worldview Technology Partners, intend to offer shares of common stock for sale in an underwritten secondary offering)</li><li><strong>TWO</strong> -1.4% (to offer up to $250 mln of convertible senior notes due 2022; issues statement on recent developments, sees year-ending book value per diluted common share of $9.73-9.83 following Q4 market volatility)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>DG</strong> -1.1% (downgraded to Neutral from Buy at BofA/Merrill)</li></ul>"